Z. Yin, D. Chen, S. Liang, X. Li, Neoadjuvant therapy for hepatocellular carcinoma. J. Hepatocell. Carcinoma 9, 929–946 (2022)

Article  PubMed  PubMed Central  Google Scholar 

A.S. Qari, A.H. Mowais, S.M. Alharbi, M.J. Almuayrifi, A.A. Al Asiri, S.A. Alwatid, A.A. Aljohani, R.M. Alanazi, F. Al Thoubaity, Adjuvant and neoadjuvant therapy for breast cancer: a systematic review. Eur J Breast Heal 20(3), 156–166 (2024)

Article  Google Scholar 

Y. Al-Khazraji, M.A. Muzammil, S. Javid, A.V. Tangella, N.V. Gohil, H. Saifullah, S.G. Kanagala, F. Fariha, A. Muneer, S. Ahmed, A. Shariq, Novel regimens and treatment strategies in neoadjuvant therapy for colorectal cancer: a systematic review. Int J Heal. Sci 18(5), 43–58 (2024)

Google Scholar 

R.P. Dang, D. McFarland, V.H. Le, N. Camille, B.A. Miles, M.S. Teng, E.M. Genden, K.J. Misiukiewicz, Neoadjuvant therapy in differentiated thyroid cancer. Int. J. Surg. Oncol. 2016, 3743420 (2016)

PubMed  PubMed Central  Google Scholar 

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016). https://doi.org/10.1089/thy.2015.0020

Article  PubMed  PubMed Central  Google Scholar 

R.R. Naik, A.K. Shakya, Exploring the chemotherapeutic potential of currently used kinase inhibitors: an update. Front. Pharmacol. 13, 1064472 (2023). https://doi.org/10.3389/fphar.2022.1064472

Article  CAS  PubMed  PubMed Central  Google Scholar 

M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.-B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372(7), 621–630 (2015)

Article  PubMed  Google Scholar 

R. Elisei, M.J. Schlumberger, S.P. Müller, P. Schöffski, M.S. Brose, M.H. Shah, L. Licitra, B. Jarzab, V. Medvedev, M.C. Kreissl, B. Niederle, E.E.W. Cohen, L.J. Wirth, H. Ali, C. Hessel, Y. Yaron, D. Ball, B. Nelkin, S.I. Sherman, Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. 31(29), 3639–3646 (2013)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S.A. Wells, B.G. Robinson, R.F. Gagel, H. Dralle, J.A. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab, Vasselli JR, J. Read, P. Langmuir, A.J. Ryan, M.J. Schlumberger, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30(2), 134–141 (2012)

Article  CAS  PubMed  Google Scholar 

M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, C. de la Fouchardiere, F. Pacini, R. Paschke, Y.K. Shong, S.I. Sherman, J.W.A. Smit, J. Chung, C. Kappeler, C. Peña, I. Molnár, M.J. Schlumberger, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940), 319–328 (2014)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M.F. Mosele, C.B. Westphalen, A. Stenzinger, F. Barlesi, A. Bayle, I. Bièche, J. Bonastre, E. Castro, R. Dienstmann, A. Krämer, A.M. Czarnecka, F. Meric-Bernstam, S. Michiels, R. Miller, N. Normanno, J. Reis-Filho, J. Remon, M. Robson, E. Rouleau, A. Scarpa, C. Serrano, J. Mateo, F. André, Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol 35(7), 588–606 (2024)

Article  CAS  PubMed  Google Scholar 

D.M. Hartl, S. Zago, S. Leboulleux, H. Mirghani, D. Déandreis, E. Baudin, M. Schlumberger, Resection margins and prognosis in locally invasive thyroid cancer. Head Neck 36(7), 1034–1038 (2014)

Article  PubMed  Google Scholar 

K.C. Bible, E. Kebebew, J. Brierley, J.P. Brito, M.E. Cabanillas, T.J. Clark, A. Di Cristofano, R. Foote, T. Giordano, J. Kasperbauer, K. Newbold, Y.E. Nikiforov, G. Randolph, M.S. Rosenthal, A.M. Sawka, M. Shah, A. Shaha, R. Smallridge, C.K. Wong-Clark, 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 31(3), 337–386 (2021)

Article  PubMed  PubMed Central  Google Scholar 

Z.W. Baloch, S.L. Asa, J.A. Barletta, R.A. Ghossein, C.C. Juhlin, C.K. Jung, V.A. LiVolsi, M.G. Papotti, M. Sobrinho-Simões, G. Tallini, O. Mete, Overview of the 2022 WHO classification of thyroid neoplasms. Endocr. Pathol. 33(1), 27–63 (2022)

Article  PubMed  Google Scholar 

M. Tsuboi, H. Takizawa, M. Aoyama, A. Tangoku, Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: a case report. Int. J. Surg. Case Rep. 41, 89–92 (2017)

Article  PubMed  PubMed Central  Google Scholar 

D.L.S. Danilovic, G. Castro, F.S.R. Roitberg, F.A.B. Vanderlei, F.A. Bonani, R.M.C. Freitas, G.B. Coura-Filho, R.Y. Camargo, M.A. Kulcsar, S. Marui, A.O. Hoff, Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer. Arch. Endocrinol. Metab. 62(3), 370–375 (2018)

PubMed  PubMed Central  Google Scholar 

K.E. Stewart, M.W.J. Strachan, D. Srinivasan, M. Macneill, L. Wall, I.J. Nixon, Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report. Eur. Thyroid J. 8(2), 102–107 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Gay, E. Monti, C. Trambaiolo Antonelli, M. Mora, B. Spina, G. Ansaldo, M. Teliti, M. Comina, L. Conte, M. Minuto, E. Varaldo, S. Zupo, B. Massa, S. Morbelli, M. Giusti, Case report: Lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma. Futur. Oncol. 15(24s), 13–19 (2019)

Article  CAS  Google Scholar 

M.E. Cabanillas, R. Ferrarotto, A.S. Garden, S. Ahmed, N.L. Busaidy, R. Dadu, M.D. Williams, H. Skinner, G.B. Gunn, H. Grosu, P. Iyer, M.C. Hofmann, M. Zafereo, Neoadjuvant BRAF-and immune-directed therapy for anaplastic thyroid carcinoma. Thyroid 28(7), 945–951 (2018)

Article  PubMed  PubMed Central  Google Scholar 

D. Barbaro, P. Lapi, P. Viacava, L. Torregrossa, Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe. BMJ Case Rep 13(12), e236934 (2020). https://doi.org/10.1136/bcr-2020-236934

Article  PubMed  PubMed Central  Google Scholar 

J. Kent, P. Erwin, D. Haraf, C.Y. Liao, J. Durham, P. Angelos, N. Agrawal, B.J. Baird, M.L.L. Madariaga, Laryngotracheal resection after B-Raf proto-oncogene inhibition for anaplastic thyroid carcinoma. Annals of Thoracic Surgery 115, e117–e120 (2023)

Article  PubMed  Google Scholar 

I. Damásio, J. Simões-Pereira, S. Donato, M. Horta, B.M. Cavaco, M. Rito, P. Gomes, V. Leite, Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report. Eur Thyroid J 12(1), e220179 (2022)

PubMed  PubMed Central  Google Scholar 

E. Maurer, F. Eilsberger, S. Wächter, J. Riera Knorrenschild, A. Pehl, K. Holzer, A. Neubauer, M. Luster, D.K. Bartsch, Mutation-based, short-term “neoadjuvant” treatment allows resectability in stage IVB and C anaplastic thyroid cancer. Eur. Arch. Oto-Rhino-Laryngology 280(3), 1509–1518 (2023)

Article  Google Scholar 

Y. Song, Y. Bai, J. Wang, G. Xu, T. Wang, B. Zhang, Pathologic complete response after neoadjuvant v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibition combined with immunotherapy therapy for anaplastic thyroid carcinoma: a case report and literature review. Endocr. J. 70(2), 223–228 (2023)

Article  PubMed  Google Scholar 

J.M. Cleary, P.M. Sadow, G.W. Randolph, E.L. Palmer, T.P. Lynch, Y.E. Nikiforov, L.J. Wirth, Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib. J. Clin. Oncol. 28(23), e390–e392 (2010). https://doi.org/10.1200/JCO.2009.27.4225

Article  PubMed  Google Scholar 

H. Golingan, B. Hunis, A.C. Golding, D.N. Bimston, R.M. Harrell, Neoadjuvant lenvatinib in advanced unresectable medullary thyroid carcinoma: a case report. AACE Clin. Case Reports 6(2), e73–e78 (2020)

Article  Google Scholar 

Y. Jozaghi, M. Zafereo, M.D. Williams, M.K. Gule-Monroe, J. Wang, E.G. Grubbs, A. Vaporciyan, M.I. Hu, N. Busaidy, R. Dadu, S.G. Waguespack, V. Subbiah, M. Cabanillas, Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck 43(1), E7–E12 (2021)

Article  PubMed  Google Scholar 

R. Kothari, S. Kreimer, H. Nadel, H. Seeley, G. Hartman, K.D. Meister, Use of neoadjuvant vandetanib in aggressive pediatric medullary thyroid carcinoma. JCO Precis. Oncol. 8, e2300257 (2024). https://doi.org/10.1200/po.23.00257

Article  PubMed  Google Scholar 

C.F. Nava, R.S. Scheffel, A.P. Cristo, C.V. Ferreira, S. Weber, A.B. Zanella, F.C. Paixão, A. Migliavaca, J.R. Guimarães, M.S. Graudenz, J.M. Dora, A.L. Maia, Neoadjuvant multikinase inhibitor in patients with locally advanced unresectable thyroid carcinoma. Front. Endocrinol. (Lausanne). 10, 712 (2019). https://doi.org/10.3389/fendo.2019.00712

Article  PubMed  PubMed Central  Google Scholar